/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Akebia Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.55 0.068(6.8%) AKBA at 04 Dec 2025 04:25 PM Drug Manufacturers - Specialty & Generic
Lowest Today 1.46
Highest Today 1.58
Today’s Open 1.46
Prev. Close 1.47
52 Week High 4.08
52 Week Low 1.45
Day’s Range: Low 1.46 High 1.58
52-Week Range: Low 1.45 High 4.08
1 day return -
1 Week return -0.63
1 month return -24.46
3 month return -47.84
6 month return -56.73
1 year return -22.79
3 year return +436.26
5 year return -48.69
10 year return -

Institutional Holdings

BlackRock Inc 6.93

Vanguard Group Inc 5.51

State Street Corp 3.02

Vanguard Total Stock Mkt Idx Inv 2.94

Geode Capital Management, LLC 2.29

iShares Russell 2000 ETF 2.29

Morgan Stanley - Brokerage Accounts 2.01

Renaissance Technologies Corp 1.58

Goldman Sachs Group Inc 1.48

SPDR® S&P Biotech ETF 1.17

MPM Oncology Impact Management LP 1.09

Nuveen, LLC 1.02

Franklin Resources Inc 1.01

Vanguard Institutional Extnd Mkt Idx Tr 0.98

Fidelity Small Cap Index 0.94

Citadel Advisors Llc 0.87

Millennium Management LLC 0.82

Northern Trust Corp 0.81

Nantahala Capital Management, LLC 0.75

Foord Global Equity (Lux) A 0.75

Great Point Partners LLC 0.75

iShares Russell 2000 Value ETF 0.74

Affinity Asset Advisors, LLC 0.74

Foord Global Equity Class B 0.69

Nuveen Quant Small Cap Equity R6 0.68

Qube Research & Technologies 0.65

JPMorgan Chase & Co 0.62

Franklin Biotechnology Discv A(acc)USD 0.61

The Informed Momentum Company (formerly EAM Investors) 0.55

Fidelity Extended Market Index 0.49

Jacobs Levy Equity Management, Inc. 0.45

Vanguard Russell 2000 ETF 0.45

RTW Biotech Opportunities Ord 0.45

Franklin Biotechnology Discovery A 0.34

State St Russell Sm Cap® Indx SL Cl I 0.33

IMC US Small Cap 0.29

Vanguard Health Care ETF 0.28

Fidelity Enhanced Small Cap ETF 0.26

Schwab Small Cap Index 0.24

NT R2000 Index Fund - NL 0.23

Market Status

Strong Buy: 3

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 390.09 M

PB Ratio 9.6022

PE Ratio 0.0

Enterprise Value 285.51 M

Total Assets 220.67 M

Volume 4130252

Company Financials

Annual Revenue FY23:194327000 194.3M, FY22:292602000 292.6M, FY21:213578000 213.6M, FY20:295307000 295.3M, FY19:335001000 335.0M

Annual Profit FY23:143044000 143.0M, FY22:207806000 207.8M, FY21:60184000 60.2M, FY20:-601000 -0.6M, FY19:189665000 189.7M

Annual Net worth FY23:-56946000 -56.9M, FY22:-106009000 -106.0M, FY21:-244870000 -244.9M, FY20:-349867000 -349.9M, FY19:-279659000 -279.7M

Quarterly Revenue Q3/2025:58766000 58.8M, Q2/2025:62472000 62.5M, Q1/2025:57336000 57.3M, Q3/2024:37428000 37.4M, Q2/2024:43648000 43.6M

Quarterly Profit Q3/2025:49065000 49.1M, Q2/2025:52553000 52.6M, Q1/2025:49711000 49.7M, Q3/2024:23267000 23.3M, Q2/2024:26202000 26.2M

Quarterly Net worth Q3/2025:540000 0.5M, Q2/2025:247000 0.2M, Q1/2025:6112000 6.1M, Q3/2024:-20039000 -20.0M, Q2/2024:-8582000 -8.6M

Fund house & investment objective

Company Information Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Organisation Drug Manufacturers - Specialty & Generic

Employees 181

Industry Drug Manufacturers - Specialty & Generic

CEO Mr. John P. Butler MBA

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow